09.07.2021 • News

Nouryon Completes Spin-out of Nobian

Nouryon, the former specialty chemical business of AkzoNobel, has completed the spin-out of its base chemicals business, Nobian. The latter company will be held separately by Nouryon’s private equity owners, the Carlyle Group and GIC.

As part of the spin-out transaction, Nouryon repaid € 1.5 billion of its debt with the proceeds of a completed external financing by Nobian. To help ensure a seamless transformation, Nouryon will continue to provide transitional support services to Nobian across multiple functional areas.

Nouryon, focused globally, specializes in sustainable solutions for manufacturing everyday products in areas such as personal care, cleaning goods, paints & coatings, agriculture and food, along with pharmaceuticals and building products. The company with about 7,900 employees  in more than 80 countries had sales revenues of €3.7 billion in 2020.

Nobian, with a more European focus, produces base chemicals for industries ranging from construction and cleaning to pharmaceuticals and water treatment. The company employs about 1,600 people and posted revenues of €1 billion in 2020.

Charlie Shaver, chairman and CEO of Nouryon and chairman of Nobian, said the split will allow Nouryon to benefit from an “increasingly specialized and leading portfolio in Performance Formulations and Technology Solutions, driven by resilient and growing end-markets.”

Author: Dede Williams, Freelance Journalist

 

Nouryon, AkzoNobel’s former specialty chemical business, has completed the...
Nouryon, AkzoNobel’s former specialty chemical business, has completed the spin-out of its base chemicals business, Nobian. The latter will be held separately by Nouryon’s equity owners, the Carlyle Group and GIC. As part of the spin-out, Nouryon repaid € 1.5 billion of its debt. (c) Nouryon

Company

Logo:

Nouryon

Christian Neefestraat 2
1077 WW Amsterdam
Netherlands

Company contact







From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read